Terms: = Thyroid cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Staging
13 results:
1. Development and Assessment of a Novel Core Biopsy-Based Prediction Model for Pathological Complete Response to Neoadjuvant Chemotherapy in Women with Breast cancer.
Lan A; Chen J; Li C; Jin Y; Wu Y; Dai Y; Jiang L; Li H; Peng Y; Liu S
Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674372
[TBL] [Abstract] [Full Text] [Related]
2. The complementary role of lymphovascular invasion and perineural invasion in the TNM staging process of rectal cancer.
Chen T; Wang M; Cheng X; Wang Y; Jiang Y; Fang X; Xiao H
Medicine (Baltimore); 2022 Sep; 101(39):e30687. PubMed ID: 36181060
[TBL] [Abstract] [Full Text] [Related]
3. A rare association of two endocrine tumours: non-functional oncocytic adrenocortical carcinoma and Papillary thyroid carcinoma.
Ruiz-Sánchez JG; Parra Ramírez P; Lisbona Catalán A
Horm Mol Biol Clin Investig; 2021 Mar; 42(2):199-201. PubMed ID: 33675218
[TBL] [Abstract] [Full Text] [Related]
4. [Tumors of the thyroid gland. Proposal for the management and study of samples from patients with thyroid neoplasms].
Cameselle-Teijeiro JM; Bella Cueto MR; Eloy C; Abdulkader I; Amendoeira I; Matías-Guiu X; Sobrinho-Simões M
Rev Esp Patol; 2020; 53(1):27-36. PubMed ID: 31932006
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Markers Involved in Tumorigenesis of thyroid Carcinoma: Focus on Aggressive Histotypes.
Penna GC; Vaisman F; Vaisman M; Sobrinho-Simões M; Soares P
Cytogenet Genome Res; 2016; 150(3-4):194-207. PubMed ID: 28231576
[TBL] [Abstract] [Full Text] [Related]
6. Correlation of BRAF mutation and SUV
Ozderya A; Temizkan S; Gul AE; Ozugur S; Sargin M; Aydin K
Endocrine; 2017 Jan; 55(1):215-222. PubMed ID: 27696232
[TBL] [Abstract] [Full Text] [Related]
7. ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome.
Tavares C; Melo M; Cameselle-Teijeiro JM; Soares P; Sobrinho-Simões M
Eur J Endocrinol; 2016 Apr; 174(4):R117-26. PubMed ID: 26510840
[TBL] [Abstract] [Full Text] [Related]
8. [Histological and immunohistochemical profile of sporadic and familial medullary thyroid carcinoma].
Ríos A; Rodríguez JM; Febrero B; Acosta Ortega JM; Torregrosa N; Balsalobre M; Parrilla P
Endocrinol Nutr; 2011 Dec; 58(10):521-8. PubMed ID: 22047736
[TBL] [Abstract] [Full Text] [Related]
9. [Prognostic value of clinical, histopathological and immunohistochemical features in medullary thyroid cancer].
Ríos A; Rodríguez JM; Febrero B; Acosta JM; Torregrosa N; Parrilla P
Med Clin (Barc); 2012 Sep; 139(7):277-83. PubMed ID: 22032817
[TBL] [Abstract] [Full Text] [Related]
10. [Evaluation of p53 and soluble Fas ligand (sFasL) serum level concentration as indicators of apoptosis in serum of patients with benign and malignant primary follicular thyroid tumors].
Kołomecki K; Maciaszczyk P; Stepień H; Cywiński J; Cielecka J; Stepień T; Kuzdak K
Endokrynol Pol; 2006; 57(4):320-5. PubMed ID: 17006831
[TBL] [Abstract] [Full Text] [Related]
11. p53 concentration and soluble FasL (sFasL) serum level as indicators of apoptosis in patients with benign and malignant thyroid tumors.
Kolomecki K; Maciaszczyk P; Stepien H; Stepien T; Kuzdak K; Ulanska J
Bratisl Lek Listy; 2005; 106(10):297-300. PubMed ID: 16541608
[TBL] [Abstract] [Full Text] [Related]
12. thyroid carcinoma.
Gillenwater AM; Weber RS
Cancer Treat Res; 1997; 90():149-69. PubMed ID: 9367082
[TBL] [Abstract] [Full Text] [Related]
13. Molecular approach to rapid assessment of p53 tumor suppressor mutations in esophageal tumors from stained histological slides.
Whetsell LH; Ringer DP; Schaefer FV
Diagn Mol Pathol; 1994 Jun; 3(2):132-41. PubMed ID: 7520333
[TBL] [Abstract] [Full Text] [Related]
